IDH1 and central nervous system cancer: Notably, IDH1/2 mutations induce abnormal accumulation of 2-hydroxyglutarate (2-HG), which disrupts epigenetic modifications and promotes metabolic reprogramming, serving as a hallmark of low-grade gliomas (8).